Hypoactive Sexual Desire Disorder (HSDD): Emergency Symptoms, Full Guide, and How to Manage It

Does HSDD Ever Cause a Medical Emergency?

HSDD itself does not produce life-threatening physical symptoms. The condition is defined by a persistent absence of sexual desire that causes personal distress, and that definition does not map onto 911-level crises the way chest pain or stroke symptoms do. Still, several overlapping situations connected to HSDD or its treatments can escalate to a true emergency.

Call 911 or go to an emergency room immediately if you experience any of the following:

• Thoughts of suicide or self-harm. The psychological burden of HSDD is real. In a 2008 cross-sectional study of 952 women, those with HSDD reported significantly lower health-related quality of life scores and higher rates of emotional distress than those without the disorder. If distress reaches the level of suicidal thinking, this is a psychiatric emergency.
• Sudden severe nausea, vomiting, or loss of consciousness after a bremelanotide injection. Bremelanotide (Vyleesi) carries a known risk of transient nausea in up to 40% of users, but fainting or unresponsiveness is not expected and warrants emergency evaluation.
• Severe hypotension or chest tightness after combining flibanserin with alcohol or a CYP3A4 inhibitor. The FDA black-box warning for flibanserin (Addyi) specifically names hypotension and syncope as risks when the drug is combined with alcohol or moderate-to-strong CYP3A4 inhibitors. A woman who faints or cannot be roused after taking flibanserin with alcohol needs emergency care.
• New-onset severe hypertension. Bremelanotide transiently raises systolic blood pressure by an average of 6 mmHg. Women with uncontrolled or high-baseline hypertension who notice a sudden severe headache, visual changes, or chest pain after a dose should seek emergency evaluation for hypertensive urgency.
• Acute psychosis or mania. Flibanserin acts on central serotonin and dopamine receptors. Any sudden behavioral change suggesting psychosis needs same-day psychiatric assessment.

For a mental health crisis line, you can reach the 988 Suicide and Crisis Lifeline by calling or texting 988.

What Is HSDD? The Clinical Definition

HSDD means a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked personal distress or interpersonal difficulty. The diagnosis is made only after ruling out medical causes, medication side effects, and relationship factors that fully explain the problem.

How Common Is It?

HSDD is the most common form of female sexual dysfunction. Estimates from the National Health and Social Life Survey and subsequent US probability samples suggest approximately 8 to 10% of women meet the full diagnostic threshold for HSDD at any given time, with higher rates in surgical menopause (up to 26%) and in women with premature ovarian insufficiency.

How the DSM-5 Changed the Diagnosis

The DSM-5, published in 2013, merged HSDD and Female Sexual Arousal Disorder into a single category called Female Sexual Interest/Arousal Disorder (FSIAD). Many clinicians and researchers still use the term HSDD because the FDA-approved drugs were studied under that label, and ACOG guidance frequently references it. The practical threshold remains unchanged: desire is persistently low, the woman finds this distressing, and no other condition fully explains it.

What "Distress" Actually Means

Distress is the diagnostic dividing line. A woman who has low desire and is perfectly content with it does not meet criteria for HSDD. The distress may take the form of feeling broken, grieving intimacy, experiencing relationship conflict, or feeling disconnected from her own sense of self. ACOG Practice Bulletin No. 213 states that clinician-patient discussions about sexual dysfunction should explicitly assess for personal distress rather than relying on frequency or partner expectations alone.

Sex-Specific Physiology: Why Women Are Uniquely Affected

HSDD is not a women's version of male low testosterone. Female desire is shaped by a distinct interplay of estrogen, progesterone, testosterone, and central neurotransmitters, and the same hormonal event can affect desire differently depending on context, relationship quality, and prior sexual history.

The Role of Testosterone in Women

Testosterone in women operates at concentrations roughly 10 to 15 times lower than in men, yet it acts on androgen receptors in the brain's limbic system and in genital tissue to support desire and arousal. Testosterone levels in women decline progressively from the third decade onward, reaching approximately 50% of peak levels by the late reproductive years, well before estrogen begins its menopausal fall. Bilateral oophorectomy produces an abrupt halving of circulating testosterone overnight, which is one reason surgical menopause carries higher HSDD rates than natural menopause.

Estrogen and the Central Nervous System

Estrogen modulates serotonin and dopamine pathways that govern desire. During the late luteal phase of the menstrual cycle, when estrogen falls sharply, many women notice a dip in libido. In perimenopause, erratic estrogen fluctuations can produce month-to-month swings in desire that predate the classic hot flash by years. The Menopause Society 2022 position statement on sexual health notes that genitourinary syndrome of menopause (GSM) and HSDD frequently co-occur and may each worsen the other.

Progesterone's Suppressive Effect

Progesterone, particularly the synthetic progestins used in combined hormonal contraceptives, may suppress desire by downregulating androgen receptors and increasing sex hormone-binding globulin (SHBG). Women who develop HSDD after starting an oral contraceptive pill should have this pharmacological cause considered before an HSDD diagnosis is assigned.

HSDD Across Every Life Stage

Reproductive Years (Ages 18 to ~44)

HSDD in premenopausal women is more likely to be situational or acquired rather than lifelong. Common contributors include antidepressant use (especially SSRIs and SNRIs), oral contraceptives, chronic stress, hypothyroidism, and relationship conflict. PCOS introduces an additional layer: androgen excess with insulin resistance can paradoxically co-occur with HSDD because elevated SHBG reduces free testosterone, and the psychological burden of PCOS itself dampens desire.

FDA-approved drug therapy for premenopausal women includes:

• Flibanserin (Addyi) 100 mg taken orally at bedtime daily. The SUNFLOWER and BEGONIA trials each demonstrated a modest but statistically significant increase in satisfying sexual events (SSEs) compared with placebo. In the pooled analysis of three key trials, flibanserin increased SSEs by approximately 0.5 to 1.0 events per month over placebo.
• Bremelanotide (Vyleesi) 1.75 mg subcutaneous injection taken 45 minutes before anticipated sexual activity, no more than once per 24 hours. In the RECONNECT trials, bremelanotide increased the Female Sexual Function Index (FSFI) desire subscale score and reduced distress compared with placebo.

Neither drug is approved for postmenopausal women, though off-label use is common. Neither is approved for use during pregnancy. See the Pregnancy and Lactation section below.

Trying to Conceive

Women trying to conceive cannot use flibanserin (requires reliable contraception due to embryotoxicity in animal models) or bremelanotide (insufficient human safety data). Management during this phase relies on psychosexual therapy, addressing reversible causes (thyroid disease, vitamin D deficiency, relationship counseling), and transdermal testosterone where compounded options are discussed with a provider familiar with fertility implications.

Postpartum and Lactation

Postpartum HSDD is extremely common and frequently underreported. Prolactin-driven suppression of estrogen and testosterone, physical recovery from delivery, sleep deprivation, and the psychological demands of infant care all converge. In a survey-based study, more than 60% of women reported reduced sexual desire at 3 months postpartum. Most cases resolve by 12 months without intervention. If desire has not recovered by 6 to 12 months postpartum and causes distress, formal evaluation is appropriate. Neither flibanserin nor bremelanotide has safety data in lactation; both should be avoided while breastfeeding.

Perimenopause (Typically Ages 45 to 55)

Perimenopause is the life stage at which HSDD incidence peaks in community samples. Estrogen variability, rising FSH, declining testosterone, worsening sleep, and increasing GSM symptoms all contribute. Menopausal hormone therapy (MHT) that restores estrogen may improve GSM-related pain that was secondarily suppressing desire, but MHT alone does not reliably treat HSDD. Adding low-dose transdermal testosterone is the approach most supported by evidence in this group. A 2019 systematic review and meta-analysis published in The Lancet Diabetes and Endocrinology, examining 36 randomized trials, found that transdermal testosterone significantly improved sexual function, including desire, in women with HSDD across surgical and natural menopause.

Postmenopause

Postmenopausal HSDD is addressed by The Menopause Society as a clinical priority. No testosterone product is FDA-approved for women in the US, but the International Society for the Study of Women's Sexual Health (ISSWSH) and NAMS jointly recommend off-label transdermal testosterone in postmenopausal women with HSDD when other causes have been excluded. Compounded bioidentical testosterone creams and FDA-approved male formulations used at female doses (approximately one-tenth of male dose) are the practical options. Monitoring free testosterone levels to keep them within the physiologic female range is standard of care.

HSDD and Conditions Unique to Women

PCOS

Women with PCOS face a paradox. Total testosterone is often elevated, yet free testosterone may be low due to high SHBG driven by insulin resistance and, in many cases, oral contraceptive use. Desire in PCOS correlates more strongly with body image, depression, and relationship satisfaction than with androgen levels alone. Treating insulin resistance with metformin or lifestyle intervention and addressing depression with psychotherapy may be more impactful than androgen supplementation.

Endometriosis

Dyspareunia from endometriosis creates a conditioned aversion to sexual activity that can evolve into HSDD over time. Pain with sex is not HSDD itself, but the anticipatory avoidance pattern it generates meets the distress criterion. Treating the underlying endometriosis is the first step; psychosexual therapy addresses the conditioned avoidance that persists even after pain resolves.

Postpartum Thyroiditis

Postpartum thyroiditis affects up to 10% of women in the first year after delivery. Both hypothyroid and hyperthyroid phases can suppress desire. Any postpartum woman presenting with HSDD should have thyroid-stimulating hormone (TSH) checked before attributing symptoms to hormonal or psychological causes.

Female Pattern Hair Loss and Hormonal Acne

These androgen-mediated conditions and HSDD can be linked by underlying hyperandrogenism or, conversely, by overly aggressive anti-androgen therapy (such as spironolactone) that drops testosterone below the level needed for desire. If a woman is taking spironolactone for acne or hair loss and develops HSDD, the dose and timing should be reviewed with her prescriber.

Diagnosing HSDD: What to Expect at Your Appointment

A thorough HSDD evaluation takes 20 to 40 minutes and covers sexual history, relationship context, medical and psychiatric history, medication review, and validated questionnaire scores. The Decreased Sexual Desire Screener (DSDS) is a 5-item tool validated specifically for premenopausal women with generalized acquired HSDD. The DSDS showed a sensitivity of 83.6% and specificity of 87.8% in the validation study by Clayton et al.

Laboratory tests are not diagnostic for HSDD but help exclude treatable causes:

| Test | Why It Matters | |---|---| | TSH | Hypothyroidism suppresses desire | | Free and total testosterone | Baseline before treatment; monitors therapy | | SHBG | High SHBG reduces free testosterone | | Prolactin | Hyperprolactinemia blunts desire | | Estradiol, FSH | Confirms menopausal status | | HbA1c or fasting glucose | Metabolic disease contributes to dysfunction |

How to Manage HSDD: A Tiered Approach

The WomanRx tiered framework for HSDD management organizes interventions by evidence strength and life stage:

Tier 1: Remove the suppressors Stop or switch medications that suppress desire (SSRIs, combined oral contraceptives with high-SHBG progestins, spironolactone at high doses). Treat thyroid disease, anemia, depression, and pain conditions first. This step costs nothing and sometimes resolves HSDD entirely.

Tier 2: Psychosexual therapy Cognitive behavioral therapy and mindfulness-based sex therapy have Level I evidence for improving desire and reducing distress. A randomized trial by Brotto et al. Found that mindfulness-based cognitive therapy significantly improved FSFI desire scores and reduced sexual distress in women with HSDD compared with a waitlist control. Therapy is appropriate at every life stage and carries no contraindications.

Tier 3: Pharmacotherapy

• Premenopausal: flibanserin or bremelanotide as described above.
• Peri/postmenopausal: transdermal testosterone (off-label); add low-dose vaginal estrogen if GSM co-exists.
• All stages: ospemifene (a selective estrogen receptor modulator) treats dyspareunia from GSM, which may secondarily improve desire.

Tier 4: Combination and specialist referral Refractory HSDD warrants referral to a certified sex therapist and, where available, a women's sexual medicine specialist. Combination pharmacotherapy plus psychosexual therapy outperforms either alone in the limited head-to-head data available.

Pregnancy, Lactation, and Contraception: Required Safety Information

Pregnancy

Both FDA-approved HSDD drugs carry significant pregnancy concerns.

Flibanserin (Addyi) showed embryofetal toxicity in animal studies at doses above the human therapeutic range. The FDA label for flibanserin states it is contraindicated during pregnancy and requires healthcare providers to counsel women of reproductive potential to use effective contraception. If pregnancy occurs while taking flibanserin, the drug should be stopped immediately and the pregnancy reported to the Addyi pregnancy registry.

Bremelanotide (Vyleesi) has no adequate human data in pregnancy. The FDA label for bremelanotide advises discontinuation as soon as pregnancy is recognized and notes that animal studies at high doses showed fetal harm. Because bremelanotide is taken on-demand rather than daily, a woman who realizes she is pregnant and has used it once does not need to panic, but she should stop use and discuss the exposure with her OB.

Off-label transdermal testosterone is not recommended in pregnancy. Androgen exposure during organogenesis carries a theoretical risk of virilization of a female fetus.

Lactation

Neither flibanserin nor bremelanotide has published pharmacokinetic data in human breast milk. Both should be avoided during breastfeeding until safety data exist. Postpartum women with HSDD should prioritize psychosexual therapy and treatment of reversible causes (hypothyroidism, anemia, sleep deprivation) while breastfeeding.

Contraception requirement

Women taking flibanserin who are of reproductive potential must use reliable contraception throughout treatment. This is a condition of the REMS program under which flibanserin is dispensed in the US.

Who Is Right for HSDD Treatment, and Who Should Wait?

Good candidates for pharmacotherapy

• Premenopausal women with generalized acquired HSDD (present in all partner and non-partner contexts, developed after a period of normal desire), confirmed on DSDS
• Postmenopausal women with bothersome HSDD after GSM has been treated and reversible causes excluded
• Women who have already tried psychosexual therapy and remain significantly distressed

Proceed with caution or use alternatives

• Women currently pregnant or breastfeeding (pharmacotherapy contraindicated or lacks safety data; use psychosexual therapy)
• Women with active alcohol use disorder (flibanserin black-box hypotension risk)
• Women on moderate-to-strong CYP3A4 inhibitors such as fluconazole, clarithromycin, or certain HIV medications (flibanserin contraindicated with these agents)
• Women with uncontrolled hypertension or cardiovascular disease (bremelanotide blood pressure effect)
• Women whose low desire is fully explained by relationship conflict, sexual trauma, or partner sexual dysfunction (psychosexual therapy first; pharmacotherapy does not address these root causes)

A note on the evidence gap

Women, particularly women of color and postmenopausal women, were underrepresented in the key flibanserin and bremelanotide trials. Most trial participants were White, partnered, premenopausal women in heterosexual relationships. The BEGONIA trial that supported flibanserin's approval enrolled only premenopausal women, and subgroup data by race and menopausal status were not powered for definitive conclusions. This means the effect size estimates published may not translate identically to your situation, and your clinician should discuss this honestly with you.

Talking to Your Provider: How to Start the Conversation

Many women wait years before raising HSDD with a clinician because they assume low desire is normal, expected, or untreatable. A survey published in the Journal of Sexual Medicine found that fewer than 14% of women with sexual concerns had ever discussed them with a healthcare provider. You do not need to wait until your annual well-woman exam. A telehealth visit focused specifically on sexual health is a legitimate, billable visit at WomanRx.

A simple opening script: "I've noticed my desire for sex has been absent for more than six months and it's bothering me. I'd like to talk about what's causing it and what my options are."

Your provider should take a full sexual history, review your medications, order a targeted lab panel, and discuss validated treatment options. If they dismiss the concern without assessment, you can ask to be referred to a certified sex therapist or a women's sexual medicine specialist.